{
  "id": "56c1f00def6e39474100003f",
  "type": "factoid",
  "question": "Which enzyme is inhibited by Varespladib?",
  "ideal_answer": "Varespladib is a secretory phospholipase A2 (sPLA2) inhibitor. It was tested in patients with acute coronary syndrome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23590147",
    "http://www.ncbi.nlm.nih.gov/pubmed/19697278",
    "http://www.ncbi.nlm.nih.gov/pubmed/24115030",
    "http://www.ncbi.nlm.nih.gov/pubmed/24247616",
    "http://www.ncbi.nlm.nih.gov/pubmed/23349189",
    "http://www.ncbi.nlm.nih.gov/pubmed/21602519",
    "http://www.ncbi.nlm.nih.gov/pubmed/21098449",
    "http://www.ncbi.nlm.nih.gov/pubmed/25533115",
    "http://www.ncbi.nlm.nih.gov/pubmed/24864079",
    "http://www.ncbi.nlm.nih.gov/pubmed/24419257",
    "http://www.ncbi.nlm.nih.gov/pubmed/22281412"
  ],
  "snippets": [
    {
      "text": "The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24419257",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Large-scale Phase III trials are now underway with agents that lead to marked reductions in IL-6 and C-reactive protein (such as canakinumab and methotrexate) as well as with agents that impact on diverse non-IL-6-dependent pathways (such as varespladib and darapladib). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24864079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown.OBJECTIVE: To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The potential pro-atherogenic role of PLA(2) led to the development of two small molecules, varespladib, a reversible sPLA(2) inhibitor, and darapladib, a selective Lp-PLA(2) inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the present article, the enzymatic properties and the involvement of sPLA(2) and Lp-PLA(2) in atherogenesis are reviewed, with a focus on the results of experimental studies and clinical studies with both varespladib and darapladib inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349189",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P &lt; .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602519",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups IIa, V and X, which play a pivotal role in atherosclerotic disease and inflammation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19697278",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown.OBJECTIVE: To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes.DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n\u2009=\u20092572) or placebo (n\u2009=\u20092573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012).INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies.MAIN OUTCOMES AND MEASURES: The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P\u2009=\u2009.04).CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS.TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The central hypothesis of this study was that treatment with varespladib, a small-molecule inhibitor of sPLA(2) would reduce postprocedural release of cardiac biomarkers after elective percutaneous coronary intervention.METHODS AND RESULTS: Between October 2007 and June 2009, 144 stable patients were randomized in a phase II trial to receive varespladib 500 mg PO BID or placebo 3 to 5 days before and for 5 days after elective percutaneous coronary intervention. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21098449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated whether endothelial function is attenuated after PCI and if inhibition of secretory phospholipase A2 (sPLA2) activity augments endothelial function and coronary flow reserve (CFR) in these patients.METHODS: In the sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) study, patients undergoing elective PCI were randomized to receive Varespladib (Anthera Pharmaceuticals Inc, San Mateo, CA), an inhibitor of sPLA2, or placebo 3-5 days prior to PCI and for 5 days after PCI. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22281412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet.APPROACH AND RESULTS: sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24115030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Acute inhibition of sPLA2 activity with Varespladib does not affect endothelial or microvascular function after PCI.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22281412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24115030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23590147",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4240439",
    "http://www.biosemantics.org/jochem#4240440",
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4240439",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
  ],
  "exact_answer": "secretory phospholipase A2"
}